title: Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?
authors.forename: Emilie
authors.initials: E
authors.lastname: Moreau
authors.forename: Nicolas
authors.initials: N
authors.lastname: André
authors.forename: Carole
authors.initials: C
authors.lastname: Coze
authors.forename: Laetitia
authors.initials: L
authors.lastname: Padovani
authors.forename: Cedric
authors.initials: C
authors.lastname: Mercier
authors.forename: Joseph
authors.initials: J
authors.lastname: Ciccolini
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002675:Child, Preschool; D003564:Cytidine Deaminase / Q000172:deficiency*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy*; D015275:Tumor Lysis Syndrome / Q000209:etiology*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D003564:Cytidine Deaminase; D000093542:Gemcitabine